KHN

Findings are independent of vascular risk factors

Findings underscore ’treat-to-target’ approach of lowering serum urate for gout flares

3-week intervention combined with NRT helped 1 in 5 eventually kick the habit

Results support sugemalimab as a new first-line option for metastatic NSCLC patients

Despite new studies, balance of benefits and harms of screening uncertain

Risk greatest in young males getting second dose of vaccine

Anthocyanins, flavan-3-ols show strong associations

Treatment with TNF inhibitors preferred, especially in older patients

Dosage-reduction algorithm guided corticosteroid tapering

Analysis reveals increased risk for rehospitalization and/or death

Self-reported daytime functioning better at higher dose

Researchers urge more patient education on symptoms of chest pain

Arsa-cel shows clinical benefit versus historical cohort

For patients with stage 4/5 CKD, cTnT longitudinal measures ID those at highest risk

Study 309–KEYNOTE-775 trial boosts role of lenvatinib-pembrolizumab combo in tough-to-treat disease

Survey shows those believing pandemic lies less likely, or hesitant to get vaccinated

Are system-level changes necessary to address physician mental health?

Clinicians urged to carefully assess antibody responses after vaccination in these patients

Vaccine reactogenicity profile in MS similar to general population

For patients with stage 4/5 CKD, cTnT longitudinal measures ID those at highest risk